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Summary Lung and heart transplantation has become an accepted therapeutic option
for patients with end-stage disease. However, the calcineurin-inhibitor-based immuno-
suppression often causes renal impairment. Therefore, sirolimus, a novel immunosup-
pressive agent, may serve as an alternative or complementary agent to calcineurin
inhibitors. The aim of this review was to summarize the role of sirolimus in lung and
heart transplantation. Although only a few, small studies have been conducted so far, the
drug’s mechanisms of action and low-toxicity profile make it a highly promising option.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Lung and heart transplantation has become an
accepted treatment modality for end-stage organ
disease.1 However, despite the use of traditional
immunosuppressive maintenance therapy, which
consists of cyclosporine (CsA) or tacrolimus (Tac),
azathioprine or mycophenolate mofetil, and ster-
oids, acute rejection occurs frequently, especially
in the first weeks and months after transplantation.
Although these rejection episodes usually resolve,
they are associated with substantial morbidity and
an increased incidence of chronic rejection. Be-
cause acute rejection occurs far more often after
lung transplantation than after any other form of
solid organ transplantation,2 substantial efforts
have been invested to develop new immunosup-
pressant drugs with minimal toxic side effects.
This work reviews the evidence supporting the
use of a recently approved immunosuppressive drug,
sirolimus (SRL), in heart and lung transplantation.
Mechanism of action
SRL has a similar molecular structure to Tac and
also binds to FK binding protein 12 (FKBP12)
complex. In contrast to CsA and Tac, the SRL-
FKBP12 complex has no effect on calcineurin
phosphatase. Instead, it binds to one or more
proteins known as mammalian ‘‘targets of rapamy-
cin’’ (mTOR), and subsequently inhibits both DNA
and protein synthesis, resulting in arrest of the cell
cycle in late G1 as it progresses to the S phase.3–7
Immunosuppressive properties of
sirolimus
The immunosuppressive properties of SRL have
been confirmed in both in vitro and clinical studies.
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SRL inhibits T-cell proliferation induced by cyto-
kines such as interleukin (IL)-1, -2, -3, -12 and –15,
alloantigens and mitogens in a dose-dependent
manner.3,4 It also exerts an independent action on
antigen- and cytokine-induced B-cell prolifera-
tion,5 and it decreases the synthesis of immunoglo-
bulin.6 In animal studies, rats treated with SRL at
various doses showed a longer duration of graft
viability and longer survival than nonimmunosup-
pressed controls.7,8 SRL has been found to inhibit
cytokine expression, especially IL-10, more effec-
tively than CsA9 and to be 20 to 100 times more
potent than CsA in preventing acute allograft
rejection. When SRL was combined with CsA,
cardiac and kidney allograft survival was longer
than with either drug alone, suggesting a synergis-
tic effect.10 This was also true for SRL and Tac with
regard to mouse heart tissue allografts.11
Sirolimus in heart and lung
transplantation
Several multicenter prospective randomized trials
conducted in the United States ðn ¼ 719Þ;12 globally
ðn ¼ 576Þ;13 and in Europe ðn ¼ 83Þ14 have found
SRL to be an effective immunosuppressive agent in
renal transplant recipients. However, its role in
human heart and lung transplantation has been
investigated so far only in small prospective,
uncontrolled studies (Table 1) with a total of 38
lung transplant recipients15–17 and 86 heart trans-
plant recipients.15,18–22 SRL was tested in these
trial as a potential treatment for acute or chronic
graft rejection in patients with either refractory
rejection (rescue therapy) or bronchiolitis obliter-
ans syndrome (BOS), as an alternative immunosup-
pressant agent in transplant recipients with renal
impairment and as primary immunosuppressant
immediately after lung transplantation.17
Sirolimus as a treatment for graft rejection
Cahill et al.16 in an observational controlled study,
treated 12 lung transplant recipients with bronch-
iolitis obliterans with a combination of SRL,
calcineurin inhibitor (CI), and prednisone for 24
weeks. After SRL was initiated, 58% of the patients
required a reduction in the dose of CI to maintain
appropriate CI trough concentrations. Neverthe-
less, serum creatinine levels rose in 75%. Unex-
pected adverse effects included anemia of chronic
disease (normal iron stores with no evidence of
bleeding), (100%), edema (50%), and malignancy
(17%). For the whole group, there was no differ-
ence in the change in rate of forced expiratory
volume in 1 s (FEV1) or forced expiratory flow from
the first to third quarters (FEF 25–75%) with SRL,
though individual responses varied. SRL did not
affect the decline in pulmonary function, but in
those with rapidly declining pulmonary mechanics,
SRL administration resulted in stabilization or
improvement of pulmonary function. The authors
concluded that until optimal dosing strategies and a
more complete adverse-effect profile are estab-
lished, combination therapy should be utilized
cautiously in this patient population.
Haddad et al.18 described two patients with
chronic rejection of cardiac grafts who were
refractory to the usual antirejection medications.
In both cases, SRL proved successful in suppressing
graft rejection, and these effects were maintained
even after 10 months of SRL treatment despite
significant decreases in the doses of the other
immunosuppressant drugs.
SRL was also investigated for its ability to induce
immunosuppression in heart transplant recipients
in order to decrease the incidence of acute
rejection and avoid early renal failure. In a
prospective short-term pilot study,19 42 patients
were randomized to two groups before transplan-
tation. The study group ðn ¼ 20Þ received SRL and
low dose CsA, and the control group (n¼ 22)
received high-dose CsA and azathioprine. Both
groups also received prednisone. The duration
of follow- up was 9 months. There were no epi-
sodes of acute renal failure in the study group,
whereas two patients in the control group required
hemodialysis. The number of episodes of rejection
was similar in both groups, although the study
group had a significantly lower biopsy score. The
overall infection and mortality rates were similar
as well.
The combination of SRL and Tac was studied in a
controlled, prospective trial in 25 heart transplant
recipients.20 All but three patients tolerated the
combination well. Only one acute rejection episode
was noted, and there was no increase in the
infection rate. The authors concluded that this
combination may decrease the trough level of each
of the drugs.
Together, these studies, although very small,
suggest that a SRL-based regimen could be an
effective alternative treatment for rejection in
lung and heart transplant recipients.
Sirolimus as a treatment for renal failure
SRL has no renal toxicity, which is a common
posttransplant problem associated with CI. In a
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Table 1 Sirolimus-based immunosuppression in heart and lung transplantation: Review of the literature.
Reference Organ No of
patients
Indication Follow-up
(mos)
Results Rejection Adverse events Outcome
Snell et al.15 Lung 20 RF 1 5 ceased 2 acute 35 infections
(16 pts)
7 died
Heart 5 dialysis, 15/20
improved Cr
1 chronic
Cahill et al.16 Lung 12 BOS/BO 6 Stable lung
function
Improvement in
high-risk pts
Anemia edema
malignancy
All alive
Haddad et al.17 Heart 2 Refractory
rejection
10 Lower rejection
rate
NA All alive
Zakliczynsi
et al.19
Heart 20 Induction IS 9 No RF lower Cr No increased
rejection
No more
infections
3 died (2
controls)
Mueller et al.20 Heart 25 Primary IS 16þ /-5 22 pts tolerated No increase 1 neurological
2-RF High
cholesterol
All alive
Groetzner
et al.21
Heart 25 RF 9þ /-5 Improved Cr; 3
ceased dialysis
No rejection Stable graft
function
All alive
Griffith et al.22 Heart 9 High risk (all RF,
4/9 MV)
5 Normal graft and
renal function
2 in first 2 weeks Prolonged
serious
drainage edema
All alive
Kink-Biggs
et al.17
Lung 15 Primary IS 6 No more
infections
Low incidence Bronchial
dehiscence
4 died
BO, bronchiolitis obliterans; BOS, bronchiolitis obliterans syndrome; Cr, creatinine; IS, immunosuppresion; MV, mechanically ventilated; Pts, patients; RF, renal failure.
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study of 20 lung and five heart transplant patients
with serious renal impairment who were being
treated with CI, the addition of SRL led to a
cessation of CI treatment in 48% and a substantive
reduction in CI dose in the remainder.15 After 30
days, dialysis could be stopped in four of the five
dialyzed patients, and elevated serum creatinine
levels (mean 0.29mmol/l) dropped in 15 of the 20
patients with this finding. The improvement in
creatinine level after 30 days predicted the long-
term value, whereas the starting value did not
predict either the 30-day or the long-term value.
There were two bouts of acute rejection and one
bout of chronic rejection. Sixteen patients had 35
infectious complications and 17 patients had 24
episodes of potential SRL-related toxicity; all these
events were level related and generally responded
to a dose reduction or temporary cessation of the
drug. However, the mortality rate was high (seven
deaths) and despite the authors concluded that
these deaths were related not directly to drug
toxicity of SRL, it should be interpreted carefully.
By the end of the study, 15 patients were still
taking SRL. These findings indicate that SRL may
serve as a useful alternative immunosuppressant in
transplant recipients with renal impairment who
require significant withdrawal of CI. Whether the
resulting improvement in creatinine level can be
maintained for the long term probably depends on
the balance between the acute and chronic renal
damage.
Groetzner et al.21 studied the impact of CI-free
immunosuppression and SRL treatment on renal
failure in 25 heart transplant recipients monitored
for 9 months. They found that renal function
improved significantly, and hemodialysis could be
stopped in three dialyzed patients. No acute
rejection was noted, and graft function remained
stable.
Griffith et al.22 studied the effect of SRL in nine
high-risk heart transplant recipients, of whom
four were on mechanical ventilation. All had
renal failure. Histological rejection requiring treat-
ment occurred only in three patients within the
first 2 weeks, and each was remarkably sensitive
to a minimal steroid bolus. No rejection requiring
treatment was seen in any patient after 2 weeks.
All patients had normal graft and renal function
at a median follow-up of 5 months (range 1–9).
There was, however, prolonged serous drainage
from the chest tubes and peripheral edema, which
responded to aggressive diuresis. This study
suggests that SRL may be effective in mechani-
cally supported recipients with renal failure.
Further studies using larger samples are still
needed.
Tolerability
The main clinical side effects of SRL treatment are
myelosuppression, hyperlipidemia, and over-immu-
nosuppresssion. Headache, epistaxis, diarrhea,
mild stomatitis, skin complaints, mild acne, and
polyarthalgia have also been reported. The hyper-
triglyceridaemia and hypercholesterolaemia are
reversible and can be managed by dose reduction
and/or the addition of antihyperlipidemic agents.
Two studies reported a more frequent occurrence
of herpes simplex virus infection and pneumonia
with SRL than CsA,23,24 but there was no significant
difference in the incidence rates of moderate or
severe opportunistic or common transplant-related
infections. In a global study,13 the incidence of
posttransplantation lymphoproliferative disorders
was 1.4%, which was slightly higher than found in
other groups. Several studies reported unexplained
interstitial pneumonitis associated with SRL treat-
ment in renal and liver transplant recipients.25–27
More recently, King-Biggs et al.17 reported the
occurrence of bronchial anastomotic dehiscence in
lung transplant recipients when SRL was used as
part of an immunosuppressive regimen, in combi-
nation with Tac and corticosteroids. In these cases,
SRL was initiated at the time of transplantation in
15 lung transplant recipients. This complication
was noted in four of 15 patients of whom three
died.17
Therapeutic monitoring of SRL
SRL, currently only available in liquid formulation,
has a relatively low bioavailability (15%). It has a
long half-life (63 h), justifying both a loading dose
to rapidly attain steady-state concentrations and
once daily dosing. SRL levels should be between 3.5
and 15 ng/ml.28 The successful reduction in acute
rejection associated with fixed SRL doses of 2 and
5mg/day in the US and Global trials suggests that
while desirable, routine monitoring of SRL levels in
such regimens is not essential, particularly at doses
of 2mg/day. However, monitoring is probably
necessary to ensure safe, effective concentrations
especially in the early period post transplantation,
in patients that treat withcomination of SRL and
CsA or Tac and when there are sign of toxicity.29
Summary
SRL is a potent novel immunosuppressive drug in
humans. It has been successfully used with and
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without CsA, and may serve as an alternative or
complementary agent to CI. Tac may also be an
efficient and safe partner for SRL. Although only a
few, small studies have been conducted so far in
heart and lung transplant recipients, the drug’s
mechanisms of action and low-toxicity profile make
it a highly promising option. Recent cases of
bronchial anastomotic dehiscence in de novo lung
transplant recipients raise concerns about the role
of SRL, when administered at the time of trans-
plantation, in this patient group. Until large,
prospective trials are conducted, SRL might be
better used as a rescue therapy in lung transplant
recipients or in transplant recipients with chronic
impairment in renal function.
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